ImmunityBio, Inc. Share Price

ImmunityBio, Inc. Share Price

NASDAQ: IBRX | Mid Cap
$5.99
-$0.04 (-0.66%) Last updated on 17 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

ImmunityBio, Inc. Stock Performance

Open
$5.88
Prev. Close
$6.03
Circuit Range
N/A
Day Range
$5.77 - $6.13
Year Range
$1.95 - $12.38
Volume
6,84,445
Average Traded
$6.02

ImmunityBio, Inc. Share Price Today

As of 17 November 2026, ImmunityBio, Inc.'s share price is $5.99. The stock opened at $5.88, compared to its previous close of $6.03. During today's trading session, ImmunityBio, Inc.'s share price traded between $5.77 and $6.13, with an average price of $5.95. Over the past 52 weeks, the stock has recorded a high of $12.38 and a low of $1.95. In terms of performance, ImmunityBio, Inc.'s share price has declined by 20.36% over the last six months and is up 154.14% on a year-on-year basis.

ImmunityBio, Inc. Share Price Chart

Line chart of the ImmunityBio, Inc. price trend over the selected period. The price fell overall, ranging from 5.78 to 6.13, ending at 5.99.
$5.77$6.13
L
Show Current Price
H

ImmunityBio, Inc. Stock Fundamentals & Key Indicators

Market Cap
$5.51B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.04
Revenue (TTM)
$113.29B
Return On Equity (TTM)
96.80%
Profit Margin
-310.18%
Debt to Equity
-0.37
Quarterly Earnings Growth YoY
-197.95%

ImmunityBio, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$38.29$44.21$51.24$48.84
Net Profit-$61.94-$632.78-$230.38-$184.55
Net Profit Margin-161.77%-1431.31%-449.61%-377.87%
Income ChangeN/A-921.60%63.59%19.89%

ImmunityBio, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.24$0.62$14.75$113.29
Net Profit-$416.57-$583.20-$413.56-$351.40
Net Profit Margin-173570.83%-94064.52%-2803.80%-310.18%
Income ChangeN/A-40.00%29.09%15.03%

About ImmunityBio, Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

ImmunityBio, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$8.35
$5.96
-28.11%
Oct 2026
$9.27
$8.29
-12.46%
Sep 2026
$7.83
$9.47
+12.74%
Aug 2026
$7.17
$8.40
+17.15%
Jul 2026
$8.68
$7.17
-17.96%
Jun 2026
$7.38
$8.74
+16.30%
May 2026
$6.97
$7.51
+5.85%
Apr 2026
$7.53
$7.10
-7.13%
Mar 2026
$9.66
$7.64
-21.91%
Feb 2026
$6.29
$9.79
+56.14%
Jan 2026
$2.02
$6.27
+217.47%
Dec 2025
$2.38
$1.98
-16.14%

IBRX Share Price FAQs